A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment
Metrics: PDF 1174 views | HTML 1649 views | ?
Cheng-Xiang Zhang1, Wei-Yu Zhao1, Lei Liu1, Rui-Jun Ju1, Li-Min Mu1, Yao Zhao1, Fan Zeng1, Hong-Jun Xie1, Yan Yan1, Wan-Liang Lu1
1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug System, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
Wan-Liang Lu, e-mail: email@example.com
Keywords: Functional targeting epirubicin liposomes, BBB, brain glioblastoma, neovasculatures, mechanism and efficacy
Received: April 14, 2015 Accepted: September 14, 2015 Published: September 25, 2015
The objectives of the present study were to develop functional targeting epirubicin liposomes for transferring drugs across the blood-brain barrier (BBB), treating glioblastoma, and disabling neovascularization. The studies were performed on glioblastoma cells in vitro and on glioblastoma-bearing mice. The results showed that the constructed liposomes had a high encapsulation efficiency for drugs (>95%), suitable particle size (109 nm), and less leakage in the blood component-containing system; were significantly able to be transported across the BBB; and exhibited efficacies in killing glioblastoma cells and in destroying glioblastoma neovasculature in vitro and in glioblastoma-bearing mice. The action mechanisms of functional targeting epirubicin liposomes correlated with the following features: the long circulation in the blood system, the ability to be transported across the BBB via glucose transporter-1, and the targeting effects on glioblastoma cells and on the endothelial cells of the glioblastoma neovasculature via the integrin β3 receptor. In conclusion, functional targeting epirubicin liposomes could be used as a potential therapy for treating brain glioblastoma and disabling neovascularization in brain glioblastomas.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.